BAY 2666605
Alternative Names: BAY-2666605; SLFN12 ciLatest Information Update: 28 May 2024
At a glance
- Originator Bayer
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; Protein-protein interaction modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma; Solid tumours
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Liquid)
- 28 May 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Tablet)
- 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Liquid)